Feasibility of Screening Primary Aldosteronism by Aldosterone-to-Direct Renin Concentration Ratio Derived from Chemiluminescent Immunoassay Measurement: Diagnostic Accuracy and Cutoff Value

Table 3

Anthropometric and clinical characteristics of the hypertensive patients screened in our study.

Variable	PH	PA	P value
	(n=386)	(n=64)	PH vs. PA
Age (years)			0.557
Sex (M/F)	221/165	30/34	0.122
BMI (kg/m^2)			0.358
SBP (mmHg)			0.649
DBP (mmHg)			0.103
HR (beat/minute)			0.115
Serum K^+(mmol/L)			<0.0001
Serum Na^+(mmol/L)			0.049
Urinary K^+(mmol/24h)			<0.0001
Urinary Na^+(mmol/24h)			0.273
Serum creatinine (μmol/L)			0.832
PRA (recumbent) (ng/ml/h)	1.04 (0.43-2.26)	0.20 (0.13-0.26)	< 0.0001
PRA (upright) (ng/ml/h)	2.46 (1.13-5.59)	0.41 (0.10-0.83)	< 0.0001
PRA (post ivSLT)(ng/ml/h)	0.6 (0.25-1.59)	0.16 (0.02-0.25)	< 0.0001
DRC (recumbent)(mU/L)	9.37 (3.61-19.68)	1.28 (0.54-2.72)	< 0.0001
DRC (upright) (mU/L)	20.09 (10.01-49.72)	3.52 (1.34-7.48)	< 0.0001
DRC (post ivSLT) (mU/L)	6.16 (2.07-14.03)	1.00 (0.50-2.24)	< 0.0001
(recumbent) (ng/dL)	7.84 (5.03-11.48)	11.90 (7.01-20.85)	< 0.0001
(upright) (ng/dL)	11.56 (7.84-16.73)	20.50(13.07-35.22)	< 0.0001
(post ivSLT) (ng/dL)	2.61 (2.13-3.62)	5.91 (1.96-9.50)	< 0.0001
(recumbent) (ng/dL)	7.32 (5.21-10.40)	14.15(10.00,20.95)	< 0.0001
(upright) (ng/dL)	10.70 (7.11-16.48)	21.70 (17.15-31.65)	< 0.0001
(post ivSLT) (ng/dL)	3.89 (2.80-5.10)	9.80 (7.60-14.50)	< 0.0001

PH: primary hypertension; PA: primary aldosteronism; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; K⁺: potassium; Na⁺: sodium; PRA: plasma renin activity; DRC: direct renin concentration; : plasma aldosterone concentration measured by radioimmunoassay; : plasma aldosterone concentration measured by chemiluminescent immunoassay; ivSLT: intravenous saline loading test. Age, BMI, SBP, DBP, HR, serum K⁺/Na⁺, urinary K⁺/Na⁺, and serum creatinine are expressed as mean ± standard deviation; PRA, DRC, and PAC are expressed as median (25th–75th percentiles).